Trial reportVaccine2008
Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency.
Trial report in Vaccine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 110 citations in OpenAlex.
- Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept.BMC musculoskeletal disorders · 2016Trial
- The effect of age on the response to the pneumococcal polysaccharide vaccine.BMC infectious diseases · 2010Trial
- An overview of the clinical development of the 20-valent pneumococcal conjugate vaccine in adults.Human vaccines & immunotherapeutics · 2026Review
- Rescuing age-associated vaccine hyporesponsiveness in murine and nonhuman primate models with an immunostimulatory vaccine adjuvant.Human vaccines & immunotherapeutics · 2026Article
- Insights into the heterogeneity of pneumococcal polysaccharide vaccine immunogenicity in older adults.Immunity & ageing : I & A · 2026Article
- Article
- Basal activation of ERK1/2 blunts the antimicrobial activity of neutrophils from old hosts against antibody-opsonized Streptococcus pneumoniae.Journal of leukocyte biology · 2026Article
- Association of frailty and malnutrition with pneumonia severity in PCV-13 vaccinated older adults: a single-centre experience.BMC geriatrics · 2025Article
- Evaluation of efficacy and effectiveness across the pneumococcal conjugate vaccine era.Human vaccines & immunotherapeutics · 2025Review
- Approaches to assess new pneumococcal vaccines for immunogenicity, development and licensure.Human vaccines & immunotherapeutics · 2025Review
- Zinc deficiency as possible link between immunosenescence and age-related diseases.Immunity & ageing : I & A · 2025Review
- Age-related decline in IgM responses associate with reduced opsonophagocytic activity following PCV13 vaccination.NPJ vaccines · 2025Article
- Article
- State of pneumococcal vaccine immunity.Human vaccines & immunotherapeutics · 2024Article
- Enhancing vaccine effectiveness in the elderly to counter antibiotic resistance: The potential of adjuvants via pattern recognition receptors.Human vaccines & immunotherapeutics · 2024Review
- Article
- The Impact of Immune System Aging on Infectious Diseases.Microorganisms · 2024Review
- Challenges in the Vaccination of the Elderly and Strategies for Improvement.Pathophysiology : the official journal of the International Society for Pathophysiology · 2023Review
- Reduced immunogenicity of a liveFrontiers in immunology · 2023Article
- Sero-survey on long-term care facility residents reveals increased risk of sub-optimal antibody response to BNT162b2: implications for breakthrough prevention.BMC geriatrics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The primary mode of prevention of adult disease from Streptococcus pneumoniae is vaccination with anti-capsular polysaccharide vaccine; however, its effects are less in the targeted older population than in young persons. Few studies have examined the mechanism behind this limited effectiveness. We have measured antibody concentrations and opsonization titers for multiple serotypes amongst both old adults and young, healthy controls. To avoid specificity problems associated with pneumococcal antibody ELISA, we absorbed the serum samples with c-polysaccharide and capsular polysaccharide of 22F type. Antibody concentrations were found to be similar for six out of the seven tested serotypes, while opsonization titers were significantly higher in six out of seven serotypes in the younger population. Antibody potency, as measured by the ratio of opsonization titer to antibody concentration, was found to be significantly higher for the younger subjects for all serotypes. We conclude that, while all ages of adults make similar concentrations of antibodies in response to pneumococcal vaccine, the effectiveness of those antibodies is significantly reduced in the older adult population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.